Targets › CD20
41 programs from 37 companies in 60 trials: 41 Phase 1, 10 Phase 3, 9 Phase 2; Oncology, Immunology, Neurology; next expected readout Dec 2026.
B-lymphocyte-specific membrane protein that plays a role in the regulation of cellular calcium influx necessary for the development, differentiation, and activation of B-lymphocytes. Functions as a store-operated calcium (SOC) channel component promoting calcium influx after activation by the B-cell receptor/BCR. (UniProt, P11836)
Open in Phaseline: the race on CD20, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Shanghai Junshi Bioscience Co., Ltd. | JS203 for Injection CD20 x CD3 bispecific antibody | CD20 | Phase 3 | Diffuse Large B-Cell Lymphoma; B-cell Non-Hodgkin's Lymphoma; Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma | Dec 2026 |
| AstraZeneca | surovatamig (AZD0486) Bispecific monoclonal antibody targeting CD20 and CD3E | CD19, CD3E, CD20 | Phase 3 | Large B-cell Lymphoma; Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV; Untreated Follicular Lymphoma; B-cell Non-Hodgkin Lymphoma … | Jan 2028 |
| Fondazione Italiana Linfomi - ETS | Obinutuzumab-CHOP (G-CHOP) glycoengineered anti-CD20 antibody combined with cyclophosphamide, doxorubicin, vincristin | CD20 | Phase 3 | Follicular Lymphoma | Jul 2028 |
| Fondazione Italiana Linfomi - ETS | Obinutuzumab-bendamustine (G-Benda) glycoengineered anti-CD20 monoclonal antibody combined with alkylating agent bendamustine | CD20, DNA | Phase 3 | Follicular Lymphoma | Jul 2028 |
| Fondazione Italiana Linfomi - ETS | Rituximab-bendamustine (R-Benda) anti-CD20 monoclonal antibody combined with alkylating agent bendamustine | CD20, DNA | Phase 3 | Follicular Lymphoma | Jul 2028 |
| Biocad | BCD-281 anti-CD20 monoclonal antibody | CD20 | Phase 3 | Relapsing-remitting Multiple Sclerosis (RRMS) | Dec 2028 |
| Lyell Immunopharma | Rondecabtagene autoleucel (ronde-cel) Dual-targeting CAR T-cell therapy targeting CD19 and CD20 | CD19, CD20 | Phase 3 | Large B-cell Lymphoma; Relapsed Non-Hodgkin Lymphoma | Dec 2028 |
| University Hospital Freiburg | R-MTX/AraC (MARTA) induction followed by consolidating HCT-ASCT CD20-targeted immunochemotherapy with high-dose methotrexate-based induction followed by h | CD20 | Phase 3 | Primary Central Nervous System Lymphoma | Aug 2029 |
| Shanghai Jiaolian Drug Research and Development | B007 Anti-CD20 monoclonal antibody | CD20 | Phase 2 | Generalized Myasthenia Gravis; Pemphigus; Primary Membranous Nephropathy | Dec 2026 |
| Institute of Hematology & Blood Diseases Hospital, China | CAR-T cells (single-target or dual-target directed against CD19, CD20, and/or CD CAR-T cell therapy targeting CD19, CD20, and/or CD22 | CD19, CD20, CD22 | Phase 2 | Relapsed or Refractory Aggressive B-cell Lymphoma | May 2027 |
| Daihong Liu | Polymer-Lipid Nanoparticle-Mediated Delivery of CD19/CD20 Dual-Targeting InViVoC CAR-T cell therapy delivering dual-targeting CD19/CD20 CAR mRNA via polymer-lipid nanopart | CD19, CD20 | Phase 2 | B-cell Lymphoma Refractory | Aug 2027 |
| Shanghai Chia Tai Tianqing Pharmaceutical Technology Development | TQB2825 Injection CD3/CD20 bispecific antibody | CD3, CD20 | Phase 2 | Diffuse Large Cell B-lymphoma | Feb 2028 |
| Chia Tai Tianqing Pharmaceutical Group | TQB2825 injection CD20/CD3 bispecific antibody | CD20, CD3 | Phase 1 | Diffuse Large B Cell Lymphoma | Dec 2026 |
| Cho Pharma | CHO-H01 Anti-CD20 monoclonal antibody | CD20 | Phase 1 | Non-Hodgkin Lymphoma | Dec 2026 |
| Ohio State University Comprehensive Cancer Center | Autologous Anti-CD19/CD20/CD22 CAR T-cells Multi-targeted CAR-T cell therapy targeting CD19, CD20, and CD22 | CD19, CD20, CD22 | Phase 1 | Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive | Dec 2026 |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | CT1192 Dual CD19/CD20-targeting CAR-T cell therapy | CD19, CD20 | Phase 1 | Systemic Lupus Erythematosus (SLE) | Dec 2026 |
| Medical College of Wisconsin | CAR-20/19-T cells Chimeric antigen receptor T cells targeting CD20 and CD19, expanded with IL-7/IL-15 | CD20, CD19 | Phase 1 | Non Hodgkin Lymphoma (NHL) | Feb 2027 |
| GenomeFrontier Therapeutics TW | GF-CART01 CD20/CD19-targeting CAR T cell therapy | CD20, CD19 | Phase 1 | Diffuse Large B Cell Lymphoma Relapsed | Mar 2027 |
| Adicet Therapeutics | ADI-001 Anti-CD20 CAR-T cell therapy | CD20 | Phase 1 | Rheumatoid Arthritis (RA) | Mar 2027 |
| Hebei Senlang Biotechnology | Autologous CD19/CD22/CD20 Chimeric Antigen Receptor T-cells Multi-target CAR-T cells targeting CD19, CD20, and CD22 | CD19, CD22, CD20 | Phase 1 | 19 and 22+ B Cell Hematologic Tumors | Mar 2027 |
| Johnson & Johnson (Janssen) | JNJ-80948543 T-cell redirecting trispecific antibody against CD79b, CD20, and CD3 | CD79B, CD20, CD3 | Phase 1 | Lymphoma, Non-Hodgkin | Mar 2027 |
| Shanghai AbelZeta | Prizloncabtagene autoleucel 4-1BB bispecific CAR-T cell targeting CD19 and CD20 | CD19, CD20 | Phase 1 | Relapsed/Refractory Large B-Cell Lymphoma | Mar 2027 |
| Chinese PLA General Hospital | SL1617 Injection In vivo CD19/CD20-targeted CAR T-cell immunotherapy utilizing engineered lentiviral vector | CD19, CD20 | Phase 1 | B-cell Lymphoma | Apr 2027 |
| AstraZeneca | AZD5492 CD8/TCR-based T-cell engaging antibody targeting CD20 | CD20 | Phase 1 | Systemic Lupus Erythematosus; B-cell Malignancies | May 2027 |
| The First Affiliated Hospital with Nanjing Medical University | CD19/CD20 Dual-Target in vivo CAR-T Lentiviral product Dual-target CAR-T cell therapy targeting CD19 and CD20 | CD19, CD20 | Phase 1 | Relapsed/Refractory B-cell Malignancies | Jun 2027 |
| Sumithira Vasu | Anti-CD19/CD20/CD22 CAR T-Cells Multi-targeted CAR-T cell therapy targeting CD19, CD20, and CD22 | CD19, CD20, CD22 | Phase 1 | Recurrent Acute Lymphoblastic Leukemia | Jul 2027 |
| Cellectis | UCART20x22 Allogeneic engineered T-cells expressing anti-CD20 and anti-CD22 Chimeric Antigen Receptor | CD20, CD22 | Phase 1 | B-cell Non-Hodgkin Lymphoma (B-NHL) | Aug 2027 |
| Hinge Bio | HB2198 Tetravalent bispecific anti-CD19/CD20 antibody with dual Fc domains | CD19, CD20 | Phase 1 | Healthy Volunteer; Systemic Lupus Erthematosus (SLE) | Oct 2027 |
| Shenzhen University General Hospital | CD19/CD20 CAR/TRuC-T Dual-targeted CAR/TRuC T-cell therapy against CD19 and CD20 | CD19, CD20 | Phase 1 | Relapsed/Refractory B-cell Lymphoma | Dec 2027 |
| Tianjin Medical University Cancer Institute and Hospital | LUCAR-G39D Dual-targeted CAR-T cell therapy targeting CD19 and CD20 | CD19, CD20 | Phase 1 | B-Cell Non-Hodgkin Lymphoma-Recurrent | Jun 2028 |
| Sun Yat-sen University | R-CMOP Regimen Rituximab (anti-CD20 antibody) combined with cyclophosphamide, liposomal mitoxantrone, vin | CD20 | Phase 1 | Diffuse Large B-Cell Lymphoma | Aug 2028 |
| National Cancer Institute (NCI) | Anti-CD19 and anti-CD20 bicistronic CAR T cells bicistronic CAR T cells targeting CD19 and CD20 | CD19, CD20 | Phase 1 | Chronic Lymphocytic Leukemia | Dec 2028 |
| Poseida Therapeutics | P-CD19CD20-ALLO1 Allogeneic CAR-T cells targeting CD19 and CD20 | CD19, CD20 | Phase 1 | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Mar 2029 |
| AvenCell Therapeutics | Allo-QuadCAR01-T Allogeneic CAR-T cell therapy targeting CD19/CD20 | CD19, CD20 | Phase 1 | Lymphoma Diffuse Large B-cell | Apr 2029 |
| Roche | P-CD19CD20-ALLO1 allogeneic CAR-T cell therapy targeting CD19 and CD20 | CD19, CD20 | Phase 1 | Multiple Sclerosis | Aug 2032 |
| Fred Hutchinson Cancer Center | CD20-specific CAR T-cell therapy anti-CD20 CAR-T cell therapy | CD20 | Phase 1 | Recurrent B-Cell Non-Hodgkin Lymphoma | Mar 2039 |
| Shenzhen University General Hospital | CD19/CD20-CAR.p40-T Dual-targeting CD19/CD20 chimeric antigen receptor T cell therapy | CD19, CD20 | Phase 1 | Relapsed/Refractory B-cell Lymphoma | – |
| Han weidong | Decitabine-primed Tandem CAR19/20 engineered T cells Tandem CAR-T cell therapy targeting CD19 and CD20, primed with decitabine | CD19, CD20 | Phase 1 | Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma | – |
| Guangzhou Excelmab | EX103 CD3 and CD20 bispecific monoclonal antibody | CD3E, CD20 | Phase 1 | CD20-positive Non-Hodgkin Lymphoma | – |
| Gilead Sciences | INT2104 CD20-targeting CAR (chimeric antigen receptor) delivered by lentiviral vector | CD20 | Phase 1 | Lymphomas Non-Hodgkin's B-Cell | – |
| Zhejiang Teruisi Pharmaceutical | TRS005 Anti-CD20 monoclonal antibody-MMAE antibody-drug conjugate | CD20, MMAE | Phase 1 | CD20-positive B-cell Non-Hodgkin Lymphoma | – |
Lymphoma, Non-Hodgkin (3) Primary Membranous Nephropathy (3) Follicular Lymphoma (3) Large B-cell Lymphoma (2) B-cell Non-Hodgkin Lymphoma (2) Relapsed/Refractory B-cell Lymphoma (2) Diffuse Large B-Cell Lymphoma (2) Generalized Myasthenia Gravis (1) Pemphigus (1) Relapsed Non-Hodgkin Lymphoma (1) Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV (1) Untreated Follicular Lymphoma (1)
mixed (13), small molecule (12), other (9), antibody (4), protein or peptide (2)
Fondazione Italiana Linfomi - ETS (3) AstraZeneca (2) Shenzhen University General Hospital (2) Johnson & Johnson (Janssen) (1) Shanghai Jiaolian Drug Research and Development (1) Lyell Immunopharma (1) Daihong Liu (1) Zhejiang Teruisi Pharmaceutical (1) Institute of Hematology & Blood Diseases Hospital, China (1) AvenCell Therapeutics (1) Adicet Therapeutics (1) Cellectis (1) National Cancer Institute (NCI) (1) Medical College of Wisconsin (1) Fred Hutchinson Cancer Center (1) Chinese PLA General Hospital (1) The First Affiliated Hospital with Nanjing Medical University (1) Sun Yat-sen University (1) Biocad (1) Han weidong (1)
CD19 (22) CD22 (5) CD3 (3) CD3E (2) DNA (2) CD79B (1) MMAE (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.